title: Reading toddlers: Noticing and recognising more

authors: White, Elizabeth Jayne

subjects: toddler

abstract: When I think of literacy, the idea of 'reading' some sort of language system – be it oral or written word - springs to mind. However, there are also language systems that are used by all of us throughout our lives where words are substituted with actions or are absent altogether, whether we realise it or not. This silent language is sometimes referred to as non-verbal or gestural/body communication. Though used alongside words by adults and children alike in everyday talk, its almost exclusive use is never more dominant than during our early years - in the period between infancy and childhood, which I call 'toddlerhood'.

text: Reading toddlers: Noticing and recognising more When I think of literacy, the idea of 'reading' some sort of language system – be it oral or written word - springs to mind. However, there are also language systems that are used by all of us throughout our lives where words are substituted with actions or are absent altogether, whether we realise it or not. This silent language is sometimes referred to as non-verbal or gestural/body communication. Though used alongside words by adults and children alike in everyday talk, its almost exclusive use is never more dominant than during our early years - in the period between infancy and childhood, which I call 'toddlerhood'.

year: 2010

title: Characterization and adsorption performance of New Zealand biochar for the removal of paracetamol and ibuprofen from synthetic solutions in batch and column systems

authors: Shein, Shun Lei Shwe Yee

abstract: Pharmaceuticals are a significant class of emerging organic contaminants that have been increasingly detected in aquatic environments. Their persistence and limited removal by conventional treatment methods poses considerable risks to both flora and fauna. The study investigates the adsorption performance of New Zealand-sourced biochar both raw and surface-modified for the removal of two widely used pharmaceuticals, paracetamol and ibuprofen, from aqueous solutions. With its local availability and carbon-rich structure, biochar was evaluated as an innovative solution to address the growing challenge of emerging pharmaceutical pollutants in aquatic environments. The research aimed to characterize the physicochemical properties of biochar and evaluate its adsorption capacity under batch and column configurations, addressing removal efficiency, equilibrium behaviour, kinetic mechanisms, and dynamic breakthrough performance. The biochar was instrumentally analysed by BET surface area analysis, Fourier-transform infrared spectroscopy (FTIR) and scanning electron microscopy with energy dispersive X-ray spectroscopy (SEM–EDX) to examine the biochar’s surface structure and functional groups. Premium Biochar demonstrated the highest BET surface area (308.3 m²/g), which further increased to 354 m²/g after 30% KOH activation, indicating enhanced porosity and improved availability of adsorption sites. Batch adsorption experiments revealed that paracetamol achieved higher removal efficiencies and adsorption capacities (up to 8.5 mg/g) compared to ibuprofen (maximum of 2.8 mg/g), largely due to its smaller molecular size and greater polarity. The non-linear technique using isotherm and kinetic model was used to validate the process efficiency of pharmaceuticals removal. Kinetic modelling indicated pseudo-second order and Elovich models best described the adsorption mechanisms (R² > 0.997), confirming chemisorption on heterogeneous surfaces as the dominant process. Isotherm analysis showed multilayer Freundlich adsorption for paracetamol and monolayer Langmuir adsorption for ibuprofen reflecting differences in multilayer versus monolayer adsorption behaviour. Column experiments were conducted under single-pass, closed-loop recirculation, and semi-continuous dosing modes. Single-pass continuous flow showed in rapid breakthrough at short empty bed contact times (1.6–4.5 minutes) due to hydraulic limitations. In contrast, closed-loop recirculation columns achieved up to 90% paracetamol removal and 58% ibuprofen removal under extended operation, specifically, the optimal condition when using 1 mm particle size KOH-activated biochar (1 mm KOH-modified biochar, 15 L/min flow, 500 min runtime). Semi-continuous dosing experiments demonstrated gradual adsorbent saturation with final adsorption capacities of approximately 0.43–0.57 mg/g, supporting the need for regeneration strategies in long-term applications.

text: Characterization and adsorption performance of New Zealand biochar for the removal of paracetamol and ibuprofen from synthetic solutions in batch and column systems Pharmaceuticals are a significant class of emerging organic contaminants that have been increasingly detected in aquatic environments. Their persistence and limited removal by conventional treatment methods poses considerable risks to both flora and fauna. The study investigates the adsorption performance of New Zealand-sourced biochar both raw and surface-modified for the removal of two widely used pharmaceuticals, paracetamol and ibuprofen, from aqueous solutions. With its local availability and carbon-rich structure, biochar was evaluated as an innovative solution to address the growing challenge of emerging pharmaceutical pollutants in aquatic environments. The research aimed to characterize the physicochemical properties of biochar and evaluate its adsorption capacity under batch and column configurations, addressing removal efficiency, equilibrium behaviour, kinetic mechanisms, and dynamic breakthrough performance. The biochar was instrumentally analysed by BET surface area analysis, Fourier-transform infrared spectroscopy (FTIR) and scanning electron microscopy with energy dispersive X-ray spectroscopy (SEM–EDX) to examine the biochar’s surface structure and functional groups. Premium Biochar demonstrated the highest BET surface area (308.3 m²/g), which further increased to 354 m²/g after 30% KOH activation, indicating enhanced porosity and improved availability of adsorption sites. Batch adsorption experiments revealed that paracetamol achieved higher removal efficiencies and adsorption capacities (up to 8.5 mg/g) compared to ibuprofen (maximum of 2.8 mg/g), largely due to its smaller molecular size and greater polarity. The non-linear technique using isotherm and kinetic model was used to validate the process efficiency of pharmaceuticals removal. Kinetic modelling indicated pseudo-second order and Elovich models best described the adsorption mechanisms (R² > 0.997), confirming chemisorption on heterogeneous surfaces as the dominant process. Isotherm analysis showed multilayer Freundlich adsorption for paracetamol and monolayer Langmuir adsorption for ibuprofen reflecting differences in multilayer versus monolayer adsorption behaviour. Column experiments were conducted under single-pass, closed-loop recirculation, and semi-continuous dosing modes. Single-pass continuous flow showed in rapid breakthrough at short empty bed contact times (1.6–4.5 minutes) due to hydraulic limitations. In contrast, closed-loop recirculation columns achieved up to 90% paracetamol removal and 58% ibuprofen removal under extended operation, specifically, the optimal condition when using 1 mm particle size KOH-activated biochar (1 mm KOH-modified biochar, 15 L/min flow, 500 min runtime). Semi-continuous dosing experiments demonstrated gradual adsorbent saturation with final adsorption capacities of approximately 0.43–0.57 mg/g, supporting the need for regeneration strategies in long-term applications.

year: 2025-07-06

title: The COVID-19 domestic vaccine pass: Implications for Māori

authors: Kukutai, Tahu

abstract: The New Zealand government has introduced a COVID-19 domestic vaccine pass to be used in conjunction with the COVID-19 Protection Framework. The Framework is likely to be activated soon after Cabinet meets on 29 November 2021. The pass will be necessary to access places and events that require proof of vaccination under the Framework.
This brief does not argue for or against the introduction of a domestic vaccine pass, but rather discusses key issues that it raises for Māori, and suggests actions to address them. We see four key issues:
• the lack of Māori involvement, as a Tiriti partner, on either the design or implementation of the COVID-19 domestic vaccine pass;
• disproportionate restriction on Māori mobility due to lower Māori vaccination rates;
• privacy and data security concerns;
• uneven implementation that could increase discrimination against Māori and other groups considered to pose a risk to others’ safety.
To respond to these issues we recommend that the implementation of the pass be designed in partnership with Māori and comply with Māori data sovereignty requirements. As Tiriti partners, Māori should expect that the pass will keep their communities safe, while providing opportunities to enact manaakitanga in the matrix of care, and the mana to manage their own affairs.

text: The COVID-19 domestic vaccine pass: Implications for Māori The New Zealand government has introduced a COVID-19 domestic vaccine pass to be used in conjunction with the COVID-19 Protection Framework. The Framework is likely to be activated soon after Cabinet meets on 29 November 2021. The pass will be necessary to access places and events that require proof of vaccination under the Framework.
This brief does not argue for or against the introduction of a domestic vaccine pass, but rather discusses key issues that it raises for Māori, and suggests actions to address them. We see four key issues:
• the lack of Māori involvement, as a Tiriti partner, on either the design or implementation of the COVID-19 domestic vaccine pass;
• disproportionate restriction on Māori mobility due to lower Māori vaccination rates;
• privacy and data security concerns;
• uneven implementation that could increase discrimination against Māori and other groups considered to pose a risk to others’ safety.
To respond to these issues we recommend that the implementation of the pass be designed in partnership with Māori and comply with Māori data sovereignty requirements. As Tiriti partners, Māori should expect that the pass will keep their communities safe, while providing opportunities to enact manaakitanga in the matrix of care, and the mana to manage their own affairs.

year: 2021-11-30